Proteinuria in systemic sclerosis: reversal by ACE inhibition

Area of Science:

• Nephrology
• Rheumatology
• Internal Medicine

Background:

• Kidney damage is a significant clinical issue in systemic sclerosis (SSc), often leading to poor outcomes.
• Early detection and treatment of proteinuria, similar to diabetes mellitus management, can slow kidney disease progression.
• The spontaneous course of proteinuria in SSc and the efficacy of angiotensin-converting enzyme (ACE) inhibitor therapy require further investigation.

Purpose of the Study:

• To investigate the natural progression of proteinuria in patients with systemic sclerosis (SSc).
• To evaluate the therapeutic effects of angiotensin-converting enzyme (ACE) inhibitors on proteinuria in SSc patients.

Main Methods:

• Proteinuria was assessed in SSc patients using urine protein electrophoresis.
• A cohort of 31 SSc patients with proteinuria was followed for a median of 12 months.
• ACE inhibitor treatment was administered to 23 patients; 8 remained untreated.

Main Results:

• Among 31 SSc patients with abnormal urine protein electrophoresis, 29% had microalbuminuria and 12.9% had increased total urinary protein.
• Proteinuria resolved in 74% of SSc patients treated with ACE inhibitors, versus 25% in the untreated group (p = 0.014).
• Improvements were most notable in patients with recent proteinuria diagnosis and shorter disease duration.

Conclusions:

• Initiating ACE inhibitor therapy significantly reduces proteinuria in patients with SSc and proteinuria.
• ACE inhibitors represent an effective treatment strategy for managing proteinuria in systemic sclerosis, improving renal outcomes.